Protalix BioTherapeutics (PLX) Capital Expenditures Growth (1y) (2011 - 2026)
Protalix BioTherapeutics (PLX) Capital Expenditures Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -27.93% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Protalix BioTherapeutics | 190.95 Mn | 180.16 Mn | 29.62 Mn | 78.22% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 78.22% |
| Dec 31, 2025 | -303.76% |
| Sep 30, 2025 | 16.44% |
| Jun 30, 2025 | -96.00% |
| Mar 31, 2025 | 192.47% |
| Dec 31, 2024 | 249.12% |
| Sep 30, 2024 | 64.65% |
| Jun 30, 2024 | -119.84% |
| Mar 31, 2024 | -55.21% |
| Dec 31, 2023 | -359.68% |
| Sep 30, 2023 | 260.48% |
| Jun 30, 2023 | 800.00% |
| Mar 31, 2023 | 386.57% |
| Dec 31, 2022 | 93.24% |
| Sep 30, 2022 | -63.95% |
| Jun 30, 2022 | -95.02% |
| Mar 31, 2022 | -82.64% |
| Dec 31, 2021 | -1,355.56% |
| Sep 30, 2021 | 237.25% |
| Jun 30, 2021 | 32.55% |